Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03263325 · ClinicalTrials.gov registry record
Evaluation of UDP-glucose as a Urinary Biomarker for Early Detection of Cardiac Surgery-associated Pediatric Acute Kidney Injury
A clinical trial, sponsored by Boston Children's Hospital.
- Active
- Registry status
- 305
- Enrollment target
NCT03263325 is a clinical trial that is active but no longer recruiting, run by Boston Children's Hospital. The registered enrollment target is 305 participants.
The verdict
NCT03263325 is active but no longer recruiting, sponsored by Boston Children's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 305 participants
- Enrollment target
Study Summary
Acute kidney injury (AKI) is common in children after cardiac surgery with a reported incidence of 20-40%. Pediatric AKI has been found to be associated with important short and long-term adverse outcomes. A major challenge to management of AKI after cardiac surgery and cardiopulmonary bypass is the lack of early diagnostic markers. Current diagnostic criteria for AKI in children relies exclusively on elevation of serum creatinine concentration and oliguria. Both of these markers lack sensitivity and specificity, and result in delayed detection of kidney injury. This study aims to determine if UDP-glucose can be used as a urinary biomarker to detect subclinical acute kidney injury following pediatric cardiac surgery with cardiopulmonary bypass.
Interventions
- OTHER Discarded urine sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2027-02-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03263325
The ClinicalTrials.gov registry entry for NCT03263325 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Discarded urine sample is the first listed.
NCT03263325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03263325 about?
NCT03263325 is a clinical study titled "Evaluation of UDP-glucose as a Urinary Biomarker for Early Detection of Cardiac Surgery-associated Pediatric Acute Kidney Injury". Acute kidney injury (AKI) is common in children after cardiac surgery with a reported incidence of 20-40%. Pediatric AKI has been found to be associated with important short and long-term adverse outcomes. A major challenge to management of AKI after cardiac surgery and cardiopulmonary bypass is th...
What is the current status of trial NCT03263325?
This trial is currently active not recruiting. The enrollment target is 305 participants. The study started on 2017-10-25. Estimated completion is 2027-02-01.
What interventions are being tested in trial NCT03263325?
The interventions under investigation include: Discarded urine sample (OTHER).
Who is sponsoring clinical trial NCT03263325?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.